24-hour IOP-lowering Effect of Brimonidine 0.1%

Allergan

Status and phase: Completed; Phase 4

Conditions: Open-angle Glaucoma; Ocular Hypertension

Treatments: Drug: brimonidine 0.1% (Alphagan® P)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00457795

MA-080806-2

Details and patient eligibility

About

This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

Enrollment: 15 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with open-angle glaucoma or ocular hypertension

Exclusion criteria

• allergy to brimonidine
• inability to complete 24 hour stay for monitoring

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

brimonidine 0.1%

Experimental group

Description:

brimonidine 0.1%

Treatment:

Drug: brimonidine 0.1% (Alphagan® P)